Adenosine: Does it have a neuroprotective role after all?

Brain Research Reviews

Volumn 33, Issue 2-3, 2000, Pages 258-274

  De Mendonça, Alexandre ^a   Sebastião, Ana Maria ^a   Ribeiro, Joaquim Alexandre ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Adenosine; Excitotoxicity; Hypoxia; Ischemia; Neuroprotection; Toxicity

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 BENZYL 1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID ETHYL ESTER; 6 N CYCLOPENTYLADENOSINE; 8 (4 SULFOPHENYL)THEOPHYLLINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYLTHEOPHYLLINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE DERIVATIVE; ADENOSINE KINASE; ADENOSINE RECEPTOR; CAFFEINE; CYCLOHEXYLADENOSINE; RECEPTOR SUBTYPE; THEOPHYLLINE; UNCLASSIFIED DRUG;

CELL CULTURE; CELL TYPE; CONDITIONING; ENZYME ACTIVITY; GLIA CELL; HUMAN; HYPOXIA; IN VITRO STUDY; NERVE CELL; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

ADENOSINE; ANIMALS; BRAIN CHEMISTRY; BRAIN INJURIES; EXCITATORY AMINO ACIDS; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; NEUROPROTECTIVE AGENTS; RECEPTORS, PURINERGIC P1;

EID: 0033823084     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(00)00033-3     Document Type: Review

References (179)

1. Abbracchio M.P., Ceruti S., Barbieri D., Franceschi C., Malorni W., Biondo L., Burnstock G., Cattabeni F. A novel action for adenosine: apoptosis of astroglial cells in rat brain primary cultures. Biochem. Biophys. Res. Commun. 213:1995;908-915.
2. 3 receptors and viability of astrocytes. Drug Dev. Res. 45:1998;379-386.
3. L: studies in human astroglioma cells. Biochem. Biophys. Res. Commun. 241:1997;297-304.
4. Adén U., Lindström K., Bona E., Hagberg H., Fredholm B.B. Changes in adenosine receptors in the neonatal rat brain following hypoxic ischemia. Brain Res. Mol. Brain Res. 23:1994;354-358.
5. Anderson R., Sheehan M.J., Strong P. Characterization of the adenosine receptors mediating hypothermia in the conscious mouse. Br. J. Pharmacol. 113:1994;1386-1390.
6. 2+ influx. Br. J. Pharmacol. 98:1989;225-235.
7. Arvin B., Neville L.F., Roberts P.J. 2-Chloroadenosine prevents kainic acid-induced toxicity in rat striatum. Neurosci. Lett. 93:1988;336-340.
8. Barraco R.A., Aggarwal A.K., Phillis J.W., Moron M.A., Wu P.H. Dissociation of the locomotor and hypotensive effects of adenosine analogues in the rat. Neurosci. Lett. 48:1984;139-144.
9. Barth A., Newell D.W., Nguyen L.B., Winn H.R., Wender R., Meno J.R., Janigro D. Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. Brain Res. 762:1997;79-88.
10. 1 receptor agonists as clinically viable agents for treatment of ischemic brain damage. Ann. NY Acad. Sci. 825:1997;23-29.
11. Boissard C.G., Gribkoff V.K. The effects of the adenosine reuptake inhibitor soluflazine on synaptic potentials and population hypoxic depolarizations in area CA1 of rat hippocampus in vitro. Neuropharmacology. 32:1993;149-155.
12. 1 adenosine receptor antagonist: an anatomical and behavioral study. Neuroscience. 48:1992;807-812.
13. Bona E., Adén U., Fredholm B.B., Hagberg H. The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate. Pediatr. Res. 38:1995;312-318.
14. Bona E., Adén U., Gilland E., Fredholm B.B., Hagberg H. Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology. 36:1997;1327-1338.
15. Braun N., Zhu Y., Krieglstein J., Culmsee C., Zimmermann H. Upregulation of the enzyme chain hydrolyzing extracellular ATP after transient forebrain ischemia in the rat. J. Neurosci. 18:1998;4891-4900.
16. Brodie M.S., Lee K., Fredholm B.B., Stahle L., Dunwiddie T.V. Central versus peripheral mediation of responses to adenosine receptor agonists: evidence against a central mode of action. Brain Res. 415:1987;323-330.
17. Canhão P., de Mendonça A., Ribeiro J.A. 1,3-Dipropyl-8-cyclopentylxanthine attenuates the NMDA response to hypoxia in the rat hippocampus. Brain Res. 661:1994;265-273.
18. Cao X., Phillis J.W. Adenosine A1 receptor enhancer, PD 81,723, and cerebral ischemia/reperfusion injury in the gerbil. Gen. Pharmacol. 26:1995;1545-1548.
19. Ceruti S., Barbieri D., Veronese E., Cattabeni F., Cossarizza A., Giammarioli A.M., Malorni W., Franceschi C., Abbracchio M.P. Different pathways of apoptosis revealed by 2-chloro-adenosine and deoxy-D-ribose in mammalian astroglial cells. J. Neurosci. Res. 47:1997;372-383.
20. Ceruti S., Cattabeni F., Burnstock G., Barbieri D., Monti D., Franceschi C., Malorni W., Abbracchio M.P. 2-Chloro-adenosine-induced apoptosis in rat brain neuron-glia primary cultures. Res. Commun. Mol. Pathol. Pharmacol. 87:1995;45-46.
21. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19:1999;9192-9200.
22. Costenla A.R., de Mendonça A., Sebastião A.M., Ribeiro J.A. An adenosine analogue inhibits NMDA receptor-mediated responses in bipolar cells of the rat retina. Exp. Eye Res. 68:1999;367-370.
23. Cronstein B.N., Levin R.I., Belanoff J., Weissmann G., Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78:1986;760-770.
24. 2a receptors in the rat hippocampus. Brain Res. 649:1994;208-216.
25. Danielisová V., Chavko M., Schubert P.H. Effect of propentofylline (HWA 285) on metabolic and functional recovery in the spinal cord after ischemia. Neuropharmacology. 33:1994;199-204.
26. Daval J.-L., Nicolas F. Opposite effects of cyclohexyladenosine and theophylline on hypoxic damage in cultured neurons. Neurosci. Lett. 175:1994;114-116.
27. de Mendonça A., Ribeiro J.A. Adenosine inhibits the NMDA receptor-mediated excitatory postsynaptic potential in the hippocampus. Brain Res. 606:1993;351-356.
28. de Mendonça A., Ribeiro J.A. Contribution of metabotropic glutamate receptors to the depression of excitatory postsynaptic potentials during hypoxia. Neuroreport. 8:1997;3667-3671.
29. 1 receptor activation. Neuroreport. 6:1995;1097-1100.
30. Delaney S.M., Sutherland G.R., Peeling J., Geiger J.D. Failure of 2′-deoxycoformycin to protect against transient forebrain ischemia in rat. Neurosci. Lett. 149:1993;31-34.
31. DeLeo J., Schubert P., Kreutzberg G.W. Propentofylline (HWA 285) protects hippocampal neurons of mongolian gerbils against ischemic damage in the presence of an adenosine antagonist. Neurosci. Lett. 84:1988;307-311.
32. DeLeo J., Schubert P., Kreutzberg G.W. Protection against ischemic brain damage using propentofylline in gerbils. Stroke. 19:1988;1535-1539.
33. Delledonne K.T., Sonsalla P.K. Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther. 271:1994;1320-1326.
34. 2A receptor in the rat striatum. J. Neurochem. 69:1997;315-321.
35. Domanska-Janik K., Pylowa S., Zalewska T. Coupling of adenosine receptors to adenylate cyclase in postischemic rat brain. Cell. Signal. 5:1993;337-343.
36. 6-L-phenylisopropyl-adenosine of the electrophysiological and morphological correlates of hippocampal ischaemic injury in the gerbil. Br. J. Pharmacol. 118:1996;1551-1557.
37. Donaghy K.M., Scholfield C.N. Concentration dependence of adenosine and the protection of rat cortical neurones during anoxia. Brain Res. 656:1994;174-176.
38. Dora C.D., Koch S., Sanchez A., Ruenes G., Liu S.L., Yezierski R.P. Intraspinal injection of adenosine agonists protect against L-NAME induced neuronal loss in the rat. J. Neurotrauma. 15:1998;473-483.
39. 1 receptor-mediated responses in rat hippocampus. J. Neurosci. 17:1997;607-614.
40. Dux E., Fastbom J., Ungerstedt U., Rudolphi K., Fredholm B.B. Protective effect of adenosine and a novel xanthine derivative propentophylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res. 516:1990;248-256.
41. Dux E., Schubert P., Kreutzberg G.W. Ultrastructural localization of calcium in ischemic hippocampal slices: the influence of adenosine and theophylline. J. Cereb. Blood Flow Metab. 12:1992;520-524.
42. Engler R.L. Adenosine, the signal of life? Circulation. 84:1991;951-954.
43. Evans M.C., Swan J.H., Meldrum B.S. An adenosine analogue, 2-chloroadenosine, protects against long term development of ischaemic cell loss in the rat hippocampus. Neurosci. Lett. 83:1987;287-292.
44. Fern R., Waxman S.G., Ransom B.R. Modulation of anoxic injury in CNS white matter by adenosine and interaction between adenosine and GABA. J. Neurophysiol. 72:1994;2609-2616.
45. Finn S.F., Swartz K.J., Beal M.F. 2-Chloroadenosine attenuates NMDA, kainate, and quisqualate toxicity. Neurosci. Lett. 126:1991;191-194.
46. Fowler J.C. Adenosine antagonists delay hypoxia-induced depression of neuronal activity in hippocampal brain slice. Brain Res. 490:1989;378-384.
47. Fowler J.C. Adenosine antagonists alter the synaptic response to in vitro ischemia in the rat hippocampus. Brain Res. 509:1990;331-334.
48. Frank C., de Carolis A.S., Sagratella S. Influence of adenosinergic drugs on the epileptiform and neurotoxic effects of N-methyl-D-aspartate: comparison with the effects of MK801. Arch. Int. Pharmacodyn. Ther. 327:1994;3-12.
49. B.B. Fredholm, Adenosine and neuroprotection, In: Neuroprotective Agents Cerebral Ischaemia, Academic Press, London, 1997, pp. 259-280.
50. Fuji K., Hiramatsu M., Kameyama T., Nabeshima T. Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats. Eur. J. Pharmacol. 236:1993;411-417.
51. Fujiwara F., Hirai H., Tamaki N., Okada Y. Adenosine enhances neuronal damage during deprivation of oxygen and glucose in guinea pig superior collicular slices. Neurosci. Lett. 182:1994;283-286.
52. 2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbil. Life Sci. 55:1994;PL61-65.
53. Gidday J.M., Fitzgibbons J.C., Shah A.R., Kraujalis M.J., Park T.S. Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. Pediatr. Res. 38:1995;306-311.
54. Gidday J.M., Kim Y.B., Shah A.R., Gonzales E.R., Park T.S. Adenosine transport inhibition ameliorates postischemic hypoperfusion in pigs. Brain Res. 734:1996;261-268.
55. Goldberg M.P., Monyer H., Weiss J.H., Choi D.W. Adenosine reduces cortical neuronal injury induced by oxygen or glucose deprivation in vitro. Neurosci. Lett. 89:1988;323-327.
56. Gribkoff V.K., Bauman L.A., VanderMaelen C.P. The adenosine antagonist 8-cyclopentyltheophylline reduces the depression of hippocampal neuronal responses during hypoxia. Brain Res. 512:1990;353-357.
57. Halle J.N., Kasper C.E., Gidday J.M., Koos B.J. Enhancing adenosine A1 receptor binding reduces hypoxic-ischemic brain injury in newborn rats. Brain Res. 759:1997;309-312.
58. Haun S.E., Segeleon J.E., Trapp V.L., Clotz M.A., Horrocks L.A. Inosine mediates the protective effect of adenosine in rat astrocyte cultures subjected to combined glucose-oxygen deprivation. J. Neurochem. 67:1996;2051-2059.
59. Héron A., Lekieffre D., Le Peillet E., Lasbennes F., Seylaz J., Plotkine M., Boulu R.G. Effects of an A1 adenosine receptor agonist on the neurochemical, behavioral and histological consequences of ischemia. Brain Res. 641:1994;217-224.
60. + channels in cerebral ischemic preconditioning. Proc. Natl. Acad. Sci. USA. 92:1995;4666-4670.
61. Hsu S.S.-F., Newell D.W., Tucker A., Malouf A.T., Winn H.R. Adenosinergic modulation of CA1 neuronal tolerance to glucose deprivation in organotypic hippocampal cultures. Neurosci. Lett. 178:1994;189-192.
62. 3 receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci. 19:1998;184-191.
63. Jacobson K.A., Hoffmann C., Cattabeni F., Abbracchio M.P. Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis. 4:1999;197-211.
64. Jacobson K.A., von Lubitz D.K.J.E., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17:1996;108-113.
65. Jarrott D.M., Domer F.R. A gerbil model of cerebral ischemia suitable for drug evaluation. Stroke. 11:1980;203-209.
66. Jiang N., Kowaluk E.A., Lee C.-H., Mazdiyasni H., Chopp M. Adenosine kinase inhibition protects brain against transient focal ischemia in rats. Eur. J. Pharmacol. 320:1997;131-137.
67. Johnson M.P., McCarty D.R., Chmielewski P.A. Temporal dependent neuroprotection with propentofylline (HWA 285) in a temporary focal ischemia model. Eur. J. Pharmacol. 346:1998;151-157.
68. 2A receptor antagonist. Brain Res. 800:1998;328-335.
69. 2A receptor agonists and antagonists. Neuroscience. 85:1998;229-237.
70. Jurkowitz M.S., Litsky M.L., Browning M.J., Hohl C.M. Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation. J. Neurochem. 71:1998;535-548.
71. Kano T., Katayama Y., Kawamata T., Hirota H., Tsubokawa T. Propentofylline administered by microdialysis attenuates ischemia-induced hippocampal damage but not excitatory amino acid release in gerbils. Brain Res. 641:1994;149-154.
72. Kawahara N., Ide T., Saito N., Kawai K., Kirino T. Propentofylline potentiates induced ischemic tolerance in gerbil hippocampal neurons via adenosine receptor. J. Cereb. Blood Flow Metab. 18:1998;472-475.
73. 2+-dependent manner. Neuroscience. 65:1995;947-953.
74. 3 adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 360:1999;103-108.
75. Kolvenbach R., Figge C., Godehardt E., Sandmann W. Adenosine agonists and global cerebral ischaemia. Br. J. Clin. Pharmacol. 36:1993;134-135.
76. Kulkarni J.S., Przywara D.A., Wakade T.D., Wakade A.R. Adenosine induces apoptosis by inhibiting mRNA and protein synthesis in chick embryonic sympathetic neurons. Neurosci. Lett. 248:1998;187-190.
77. Kulkarni J.S., Wakade A.R. Quantitative analysis of similarities and differences in neurotoxicities caused by adenosine and 2′-deoxyadenosine in sympathetic neurons. J. Neurochem. 67:1996;778-786.
78. Larsen A.K., Osborne N.N. Involvement of adenosine in retinal ischemia: studies on the rat. Invest. Ophthalmol. Vis. Sci. 37:1996;2603-2611.
79. 1 receptors. Brain Res. 609:1993;313-315.
80. Lee K.S., Tetzlaff W., Kreutzberg G.W. Rapid down regulation of hippocampal adenosine receptors following brief anoxia. Brain Res. 380:1986;155-158.
81. Lekieffre D., Callebert J., Plotkine M., Allix M., Boulu R.G. Enhancement of endogenous excitatory amino acids by theophylline does not modify the behavioral and histological consequences of forebrain ischemia. Brain Res. 565:1991;353-357.
82. Li B., Rosenbaum P.S., Jennings N.M., Maxwell K.M., Roth S. Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat. Exp. Eye Res. 68:1999;9-17.
83. Li B., Roth S. Retinal ischemic preconditioning in the rat: requirement for adenosine and repetitive induction. Invest. Ophtalmol. Vis. Sci. 40:1999;1200-1216.
84. Lin Y., Phillis J.W. Deoxycoformycin and oxypurinol: protection against focal ischemic brain injury in the rat. Brain Res. 571:1992;272-280.
85. Litsky M.L., Hohl C.M., Lucas J.H., Jurkowitz M.S. Inosine and guanosine preserve neuronal and glial cell viability in mouse spinal cord cultures during chemical hypoxia. Brain Res. 821:1999;426-432.
86. Lobner D., Choi D.W. Dipyridamole increases oxygen-glucose deprivation-induced injury in cortical cell culture. Stroke. 25:1994;2085-2090.
87. Logan M., Sweeney M.I. Adenosine A1 receptor activation preferentially protects cultured cerebellar neurons versus astrocytes against hypoxia-induced death. Mol. Chem. Neuropathol. 31:1997;119-133.
88. Longo R., Zeng Y.C., Sagratella S. Opposite modulation of 4-aminopyridine and hypoxic hyperexcitability by A1 and A2 adenosine receptor ligands in rat hippocampal slices. Neurosci. Lett. 200:1995;21-24.
89. 2A adenosine receptors in the hippocampus and cortex of young adult and old rats. J. Neurophysiol. 82:1999;3196-3203.
90. A-mediated actions during hypoxia in the rat hippocampus. Brain Res. 732:1996;261-266.
91. Lynch J.J., Alexander K.M., Jarvis M.F., Kowaluk E.A. Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures. Neurosci. Lett. 252:1998;207-210.
92. MacGregor D.G., Graham D.I., Jones P.A., Stone T.W. Protection by an adenosine analogue against kainate-induced extrahippocampal neuropathology. Gen. Pharmacol. 31:1998;233-238.
93. MacGregor D.G., Graham D.I., Stone T.W. The attenuation of kainate-induced neurotoxicity by chlormethiazole and its enhancement by dizocilpine, muscimol, and adenosine receptor agonists. Exp. Neurol. 148:1997;110-123.
94. MacGregor D.G., Jones P.A., Maxwell W.L., Graham D.I., Stone T.W. Prevention by a purine analogue of kainate-induced neuropathology in rat hippocampus. Brain Res. 725:1996;115-120.
95. 1 receptor. Br. J. Pharmacol. 110:1993;470-476.
96. MacGregor D.G., Stone T.W. Prevention of kainate-induced excitotoxicity by a purine analogue. Neuroreport. 3:1992;536-538.
97. 6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration. Br. J. Pharmacol. 109:1993;316-321.
98. MacGregor D.G., Stone T.W. Blockade by 1,3-dipropyl-8-cyclopentylxanthine (CPX) of purine protection against kainate neurotoxicity. Brain Res. 644:1994;339-342.
99. 1 receptors is decreased in spontaneously hypertensive rats. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 244:1993;223-230.
100. Matsumoto K., Sakaki T., Kohmura E., Hayakawa T., Yamada K. Amelioration of ischemic brain damage by the preischemic administration of propentofylline (HWA285) in a rat focal ischemia. Brain Res. 723:1996;228-230.
101. Matsuoka Y., Okazaki M., Takata K., Kitamura Y., Ohta S., Sekino Y., Taniguchi T. Endogenous adenosine protects CA1 neurons from kainic acid-induced neuronal cell loss in the rat hippocampus. Eur. J. Neurosci. 11:1999;3617-3625.
102. McGraw C.P., Crowell G.F., Howard G. Effect of aminophylline on cerebral infarction in the mongolian gerbil. Stroke. 9:1978;477-479.
103. Miller L.P., Jelovich L.A., Yao L., DaRe J., Ugarkar B., Foster A.C. Pre-and peristroke treatment with the adenosine kinase inhibitor, 5′-deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci. Lett. 220:1996;73-76.
104. 1 agonist in rat hippocampal cells. Neurosurgery. 36:1995;1003-1008.
105. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport. 9:1998;3955-3959.
106. Mori M., Nishizaki T., Okada Y. Protective effect of adenosine on the anoxic damage of hippocampal slice. Neuroscience. 46:1992;301-307.
107. Muramatsu I., Fujiwara M., Miura A., Shibata S. Reactivity of isolated canine cerebral arteries to adenine nucleotides and adenosine. Pharmacology. 21:1980;198-205.
108. 1 receptor binding in the post-ischaemic rat brain. Neuroreport. 5:1994;1453-1456.
109. Newby A.C. Adenosine as a retaliatory metabolite. Trends Biol. Sci. 9:1984;42-44.
110. Newman G.C., Hospod F.E., Trowbridge S.D., Motwani S., Liu Y. Restoring adenine nucleotides in a brain slice model of cerebral reperfusion. J. Cereb. Blood Flow Metab. 18:1998;675-685.
111. Nörenberg W., Wirkner K., Illes P. Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. Br. J. Pharmacol. 122:1997;71-80.
112. 2 receptor-mediated responses in the rat hippocampus in vitro. Eur. J. Pharmacol. 362:1998;17-25.
113. Obrenovitch T.P., Urenjak J. Altered glutamatergic transmission in neurological disorders: from high extracellular glutamate to excessive synaptic efficacy. Progr. Neurobiol. 51:1997;39-87.
114. 2A receptors and neuroprotection. Ann. NY Acad. Sci. 825:1997;30-48.
115. 1 receptors in the gerbil hippocampus: changes in the receptor density after transient ischemia. Brain Res. 345:1985;406-408.
116. 1, and muscarinic bindings in rat hippocampus after transient ischemia. Stroke. 21:1990;771-776.
117. Ostwald P., Park S.S., Toledano A.Y., Roth S. Adenosine receptor blockade and nitric oxide synthase inhibition in the retina: impact upon post-ischemic hyperemia and the electroretinogram. Vision Res. 37:1997;3453-3461.
118. 3 adenosine receptor. J. Biol. Chem. 270:1995;29607-29613.
119. Park C.K., Rudolphi K.A. Antiischemic effects of propentofylline (HWA 285) against focal cerebral infarction in rats. Neurosci. Lett. 178:1994;235-238.
120. 3H]adenosine influx: a study of three nucleoside transport systems. Biochem. Pharmacol. 46:1993;891-896.
121. Pérez-Pinzón M.A., Mumford P.L., Rosenthal M., Sick T.J. Anoxic preconditioning in hippocampal slices: role of adenosine. Neuroscience. 75:1996;687-694.
122. Phillis J.W. Adenosine in the control of the cerebral circulation. Cerebrovasc. Brain Metab. Rev. 1:1989;26-54.
123. 2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 705:1995;79-84.
124. Phillis J.W., O'Regan M.H. Deoxycoformycin prevents ischemia-induced locomotor hyperactivity in the unanesthetized gerbil. Med. Sci. Res. 16:1988;897-898.
125. Phillis J.W., O'Regan M.H. Deoxycoformycin antagonizes ischemia-induced neuronal degeneration. Brain Res. Bull. 22:1989;537-540.
126. Phillis J.W., Smith-Barbour M. The adenosine kinase inhibitor, 5-iodotubercidin, is not protective against cerebral ischemic injury in the gerbil. Life Sci. 53:1993;497-502.
127. Picano E., Abbracchio M.P. European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation? Trends Pharmacol. Sci. 19:1998;14-16.
128. Pinard E., Riche D., Puiroud S., Seylaz J. Theophylline reduces cerebral hyperaemia and enhances brain damage induced by seizures. Brain Res. 511:1990;303-309.
129. 1 receptors and K-ATP channels. J. Cereb. Blood Flow Metab. 19:1999;1296-1308.
130. Poulsen S.-A., Quinn R.J. Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. 6:1998;619-641.
131. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
132. 2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res. 831:1999;315-318.
133. Reshef A., Sperling O., Zoref-Shani E. Adenosine-induced preconditioning of rat neuronal cultures against ischemia-reperfusion injury. Adv. Exp. Med. Biol. 431:1998;365-368.
134. Rivkees S.A., Thevananther S., Hao H.P. Are A3 adenosine receptors expressed in the brain? Neuroreport. 11:2000;1025-1030.
135. Robledo P., Ursu G., Mahy N. Effects of adenosine and γ-aminobutyric acid A receptor antagonists on N-methyl-D-aspartate induced neurotoxicity in the rat hippocampus. Hippocampus. 9:1999;527-533.
136. Rother M., Erkinjuntti T., Roessner M., Kittner B., Marcusson J., Karlsson I. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement. Geriatr. Cogn. Disord. 9:(suppl 1):1998;36-43.
137. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J. Neurosci. 4:1984;1884-1891.
138. Roussel S., Pinard E., Seylaz J. Focal cerebral ischemia in chronic hypertension: no protection by (R)-phenylisopropyladenosine. Brain Res. 545:1991;171-174.
139. 1) receptors by caffeine treatment. Neurosci. Lett. 103:1989;275-280.
140. Rudolphi K.A., Keil M., Hinze H.-J. Effect of theophylline on ischemically induced hippocampal damage in mongolian gerbils: a behavioral and histopathological study. J. Cereb. Blood Flow Metab. 7:1987;74-81.
141. Rudolphi K.A., Park C.K., Rother M. Propentofylline (HWA 285), a neuroprotective glial cell modulator: pharmacologic profile. CNS Drug Rev. 3:1997;260-277.
142. Rudolphi K.A., Schubert P. Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia. Behav. Brain Res. 83:1997;123-128.
143. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Adenosine and brain ischemia. Cerebrovasc. Brain Metab. Rev. 4:1992;346-369.
144. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci. 13:1992;439-445.
145. 2+ influx in hippocampal neurons by adenosine and its blockade by LTP or ischemia. Drug Dev. Res. 28:1993;399-405.
146. Schubert P., Rudolphi K.A., Fredholm B.B., Nakamura Y. Modulation of nerve and glial function by adenosine: role in the development of ischemic damage. Int. J. Biochem. 26:1994;1227-1236.
147. Schurr A., Reid K.H., Tseng M.T., West C., Rigor B.M. Adaptation of adult brain tissue to anoxia and hypoxia in vitro. Brain Res. 374:1986;244-248.
148. 2 receptor-mediated excitatory actions on the nervous system. Progr. Neurobiol. 48:1996;167-189.
149. Sei Y., von Lubitz D.K.J.E., Abbracchio M.P., Ji X.D., Jacobson K.A. Adenosine A3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. Drug Dev. Res. 40:1997;267-273.
150. Seibel P.S., Theodore P., Kron I.L., Tribble C.G. Regional adenosine attenuates postischemic spinal cord injury. J. Vasc. Surg. 18:1993;153-158.
151. Seida M., Wagner H.G., Vass K., Klatzo I. Effect of aminophylline on postischemic edema and brain damage in cats. Stroke. 19:1988;1275-1282.
152. 2A receptor agonist CGS 21680. Drug Dev. Res. 39:1996;108-114.
153. Simon R.P., Swan J.H., Griffiths T., Meldrum B.S. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science. 226:1984;850-852.
154. Sollevi A. Cardiovascular effects of adenosine in man; possible clinical implications. Progr. Neurobiol. 27:1983;319-349.
155. Sturm C.D., Frisella W.A., Yoon K.-W. Attenuation of potassium cyanide-mediated neuronal cell death by adenosine. J. Neurosurg. 79:1993;111-115.
156. Sutherland G.R., Peeling J., Lesiuk H.J., Brownstone R.M., Rydzy M., Saunders J.K., Geiger J.D. The effects of caffeine on ischemic neuronal injury as determined by magnetic resonance imaging and histopathology. Neuroscience. 42:1991;171-182.
157. Sweeney M.I. Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Neurosci. Biobehav. Rev. 21:1997;207-217.
158. Tabuchi K., Ito Z., Wada T., Takahashi K., Hara A., Kusakari J. Effect of A1 adenosine receptor agonist upon cochlear dysfunction induced by transient ischemia. Hear. Res. 136:1999;86-90.
159. Tatlisumak T., Takano K., Carano R.A.D., Miller L.P., Foster A.C., Fisher M. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke. 29:1998;1952-1958.
160. Thorn J.A., Jarvis S.M. Adenosine transporters. Gen. Pharmacol. 27:1996;613-620.
161. van Wylen D.G.L., Park T.S., Rubio R., Berne R.M. Increases in cerebral interstitial fluid adenosine concentration during hypoxia, local potassium infusion, and ischemia. J. Cereb. Blood Flow Metab. 6:1986;522-528.
162. von Lubitz D.K.J.E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 365:1999;9-25.
163. 1 receptor agonist. Eur. J. Pharmacol. 302:1996;43-48.
164. von Lubitz D.K.J.E., Dambrosia J.M., Kempski O., Redmond D.J. Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus. Stroke. 19:1988;1133-1139.
165. von Lubitz D.K.J.E., Dambrosia J.M., Redmond D.J. Protective effect of cyclohexyl adenosine in treatment of cerebral ischemia in gerbils. Neuroscience. 30:1989;451-462.
166. 1 receptors. Eur. J. Pharmacol. 283:1995;185-192.
167. 1 receptor agonist. Eur. J. Pharmacol. 369:1999;313-317.
168. 3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur. J. Pharmacol. 367:1999;157-163.
169. 2A receptor agonist and antagonist. Eur. J. Pharmacol. 287:1995;295-302.
170. 1 receptor agonist or antagonist in cerebral ischemia. Eur. J. Pharmacol. 256:1994;161-167.
171. von Lubitz D.K.J.E., Lin R.C.-S., Paul I.A., Beenhakker M., Boyd M., Bischofberger N., Jacobson K.A. Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur. J. Pharmacol. 316:1996;171-179.
172. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 263:1994;59-67.
173. von Lubitz D.K.J.E., Marangos P.J. Cerebral ischemia in gerbils: postischemic administration of cyclohexyl adenosine and 8-sulphophenyl-theophylline. J. Mol. Neurosci. 2:1990;53-59.
174. Wakade T.D., Palmer K.C., McCauley R., Przywara D.A., Wakade A.R.
175. Zeng Y.C., Domenici M.R., Frank C., Sagratella S., de Carolis A.S. Effects of adenosinergic drugs on hypoxia-induced electrophysiological changes in rat hippocampal slices. Life Sci. 51:1992;1073-1082.
176. Zhang W.L., Lu G.W. Changes of adenosine and its A1 receptor in hypoxic preconditioning. Biol. Sign. Recept. 8:1999;275-280.
177. 2A receptors. Biochem. Pharmacol. 51:1996;957-965.
178. Zhou J.-G., Meno J.R., Hsu S.S.-F., Winn H.R. Effects of theophylline and cyclohexyladenosine on brain injury following normo- and hyperglycemic ischemia: a histopathologic study in the rat. J. Cereb. Blood Flow Metab. 14:1994;166-173.
179. Zhou Q.-Y., Li C., Olah M.E., Johnson R.A., Stiles G.L., Civelli O. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA. 89:1992;7432-7436.